Phase I Evaluation of Intravenous Ascorbic Acid in Combination with Gemcitabine and Erlotinib in Patients with Metastatic Pancreatic Cancer

• Published in: PloS one Vol. 7; no. 1; p. e29794
• Main Authors: Monti, Daniel A., Mitchell, Edith, Bazzan, Anthony J., Littman, Susan, Zabrecky, George, Yeo, Charles J., Pillai, Madhaven V., Newberg, Andrew B., Deshmukh, Sandeep, Levine, Mark
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 17.01.2012; Public Library of Science (PLoS)
• Subjects: Acids; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Ascorbic acid; Ascorbic Acid - administration & dosage; Ascorbic Acid - adverse effects; Cancer; Cancer metastasis; Cancer patients; Cancer therapies; Chemotherapy; Clinical trials; Deoxycytidine - administration & dosage; Deoxycytidine - adverse effects; Deoxycytidine - analogs & derivatives; Design standards; Dosage; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug dosages; Erlotinib; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Hydrogen peroxide; Infusions, Intravenous; Inhibitor drugs; Integrative medicine; Intravenous administration; Male; Medical treatment; Medicine; Metastases; Metastasis; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Oncology; Ovarian cancer; Pancreatic cancer; Pancreatic Neoplasms - drug therapy; Pancreatic Neoplasms - pathology; Patients; Plasma; Pulmonary Embolism - chemically induced; Quinazolines - administration & dosage; Quinazolines - adverse effects; Review boards; Safety; Studies; Targeted cancer therapy; Toxicity; Treatment Outcome; Vitamin C; United States > US; Pennsylvania

Preclinical data support further investigation of ascorbic acid in pancreatic cancer. There are currently insufficient safety data in human subjects, particularly when ascorbic acid is combined with chemotherapy. 14 subjects with metastatic stage IV pancreatic cancer were recruited to receive an eig...